Cristina Popescu

Prof. Dr. Cristina Popescu

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019
Verified
Journal Article
Closed access
CFCristina-Mihaela Farcas-Berechet
Cristina-Mihaela Farcas-Berechet
EBElena-Magdalena Berechet
Elena-Magdalena Berechet
SCStefania Craitoiu
Stefania Craitoiu
MMMihaela-Cezarina Mehedinti
Mihaela-Cezarina Mehedinti
AOAndrei Osman
Andrei Osman
MIMonica-Mihaela Iacov-Craitoiu
Monica-Mihaela Iacov-Craitoiu

Verified
Journal Article
Open access
PDF file
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
Luciana Teodora RotaruLuciana Teodora Rotaru
Luciana Teodora Rotaru
FTFlavius Nicușor Truicu
Flavius Nicușor Truicu
CSCristina Elena Singer
Cristina Elena Singer
IIIulian-Nicolae Iliescu
Iulian-Nicolae Iliescu
ONOana Elena Nicolaescu Oana Elena Nicolaescu
Oana Elena Nicolaescu Oana Elena Nicolaescu
The study evaluates the osteointegration of hydroxyapatite (HAp) and hydroxyapatite-titanium (HApTi) biocomposites implanted in the femurs of rabbits. The biocomposites were fabricated using powder metallurgy and subjected to a two-step sintering process. Scanning electron microscopy (SEM) was employed to analyze the morphology, while mesenchymal stem cells were cultured to assess cytotoxicity and proliferation. In vivo experiments involved the implantation of HAp in the left femur and HApTi in the right femur of twenty New Zealand white rabbits. Computed tomography (CT) scans, histological, immunohistochemical, and histomorphometric analyses were performed to assess bone density and osteoblast activity. Results demonstrated that HApTi implants showed superior osteointegration, with higher peri-implant bone density and increased osteoblast count compared to HAp implants. This study concluded that HApTi biocomposites have potential for enhanced bone healing and stability in orthopedic applications.

8 December 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
AOAndrei Osman
Andrei Osman
GPGabriel Sebastian Petrescu
Gabriel Sebastian Petrescu
MȚMihaela Jana Țuculină
Mihaela Jana Țuculină
IDIonela Teodora Dascălu
Ionela Teodora Dascălu
CPCristina Popescu
Cristina Popescu
Mara CarsoteMara Carsote
Mara Carsote
Our objective was to overview recent data on metabolic/endocrine disorders with respect to e-cigarette (e-cig) use. This is a narrative review; we researched English, full-length, original articles on PubMed (between January 2020 and August 2023) by using different keywords in the area of metabolic/endocrine issues. We only included original clinical studies (n = 22) and excluded case reports and experimental studies. 3 studies (N1 = 22,385; N2 = 600,046; N3 = 5101) addressed prediabetes risk; N1 showed a 1.57-fold increased risk of dual vs. never smokers, a higher risk that was not confirmed in N2 (based on self-reported assessments). Current non-smokers (N1) who were dual smokers still have an increased odd of prediabetes (a 1.27-fold risk increase). N3 and another 2 studies addressed type 2 diabetes mellitus (DM): a lower prevalence of DM among dual users (3.3%) vs. cigarette smoking (5.9%) was identified. 6 studies investigated obesity profile (4 of them found positive correlations with e-cig use). One study (N4 = 373,781) showed that e-cig use was associated with obesity in the general population (OR = 1.6, 95%CI: 1.3–2.1, p < 0.05); another (N5 = 7505, 0.82% were e-cig-only) showed that obesity had a higher prevalence in dual smokers (51%) vs. cig-only (41.2%, p < 0.05), while another (N6 = 3055) found that female (not male) e-cig smokers had higher body mass index vs. non-smokers. Data on metabolic syndrome (MS) are provided for dual smokers (n = 2): one case–control study found that female dual smokers had higher odds of MS than non-smokers. The need for awareness with respect to potential e-cig-–associated medical issues should be part of modern medicine, including daily anamnesis. Whether the metabolic/endocrine frame is part of the general picture is yet to be determined. Surveillance protocols should help clinicians to easily access the medical background of one subject, including this specific matter of e-cig with/without conventional cigarettes smoking and other habits/lifestyle elements, especially when taking into consideration metabolism anomalies.

28 July 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
Luciana Teodora RotaruLuciana Teodora Rotaru
Luciana Teodora Rotaru
Carmen Diana CimpoesuCarmen Diana Cimpoesu
Carmen Diana Cimpoesu
MCMihaela Corlade-Andrei
Mihaela Corlade-Andrei
CSCristina Elena Singer
Cristina Elena Singer
ONOana Elena Nicolaescu Oana Elena Nicolaescu
Oana Elena Nicolaescu Oana Elena Nicolaescu
This study explores the antibacterial efficacy and cytotoxicity of ciprofloxacin-functionalized bioceramic implants. We synthesized hydroxyapatite-ciprofloxacin (HACPXCS) composites and applied them to titanium substrates (Ti-HA-CPX), evaluating their performance in vitro against Staphylococcus aureus (ATCC 25923) and Escherichia coli (ATCC 25922). Antibacterial activity was assessed using the Kirby-Bauer disc diffusion method, while cytotoxicity was tested using mesenchymal stem cells. The results demonstrated that Ti-HA-CPX exhibited superior antibacterial activity, with inhibition zones of 33.5 mm (MIC 0.5 µg/mL) for Staphylococcus aureus (ATCC 25923) and 27.5 mm (MIC 0.25 µg/mL) for Escherichia coli (ATCC 25922). However, Ti-HA-CPX showed moderate cytotoxicity (80% cell viability). HACPXCS composites, whether chemically synthesized or mechanically mixed (HACPXMM), also displayed significant antibacterial activity, but with cytotoxicity ranging from low to moderate levels. Molecular docking studies confirmed strong binding affinities between ciprofloxacin and bacterial proteins, correlating with enhanced antibacterial efficacy. These findings suggest that Ti-HA-CPX composites offer a promising approach for single-stage surgical interventions in treating chronic osteomyelitis and infected fractures, balancing antibacterial effectiveness with manageable cytotoxicity.

1 January 2009
Verified
Journal Article
Closed access
CPCristina Popescu
Cristina Popescu
EIElena Ioniţă
Elena Ioniţă
CMCarmen Aurelia Mogoantă
Carmen Aurelia Mogoantă
CSCristiana Eugenia Simionescu
Cristiana Eugenia Simionescu
EPEmilia Pătru
Emilia Pătru